TriangleZanidatamab (NCT07102381)
Zanidatamab trial for HER2-positive Breast Cancer (NCT07102381). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed, untreated stage II or III HER2-positive breast cancer who plan surgery after drug treatment. Metastatic and bilateral breast cancer are excluded.
The idea: test zanidatamab, an antibody that binds two sites on HER2 to disrupt growth signals and help immune cells attack. Groups receive zanidatamab with paclitaxel; zanidatamab with docetaxel/carboplatin; or trastuzumab/pertuzumab with docetaxel/carboplatin. Researchers examine tissue after treatment for remaining cancer.
This phase 2 study plans 125 patients. Jazz Pharmaceuticals sponsors it; 34 US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.